{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T21:28:48Z","timestamp":1790803728209,"version":"4.1.0"},"reference-count":78,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,1,31]],"date-time":"2022-01-31T00:00:00Z","timestamp":1643587200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:p>Pulmonary fibrosis is a pathologic process associated with scarring of the lung interstitium. Interstitial lung diseases (ILDs) encompass a large and heterogenous group of disorders, a number of which are characterized by progressive pulmonary fibrosis that leads to respiratory failure and death. Idiopathic pulmonary fibrosis (IPF) has been described as an archetype of progressive fibrosing ILD, and the development of pirfenidone and nintedanib has been a major breakthrough in the treatment of patients with this deadly disease. Both drugs principally target scar-forming fibroblasts and have been shown to significantly slow down the accelerated decline of lung function by approximately 50%. In addition, nintedanib has been approved for patients with other progressive fibrosing ILDs and systemic sclerosis-associated ILD. However, there is still no cure for pulmonary fibrosis and no meaningful improvement of symptoms or quality of life has been shown. Advancement in research, such as the advent of single cell sequencing technology, has identified additional pathologic cell populations beyond the fibroblast which could be targeted for therapeutic purposes. The preclinical and clinical development of novel drug candidates is hampered by profound challenges such as a lack of sensitive clinical outcomes or suitable biomarkers that would provide an early indication of patient benefit. With the availability of these anti-fibrotic treatments, it has become even more difficult to demonstrate added efficacy, in particular in short-term clinical studies. Patient heterogeneity and the paucity of biomarkers of disease activity further complicate clinical development. It is conceivable that future treatment of pulmonary fibrosis will need to embrace more precision in treating the right patient at the right time, explore novel measures of efficacy, and likely combine treatment options.<\/jats:p>","DOI":"10.3389\/fphar.2022.823085","type":"journal-article","created":{"date-parts":[[2022,1,31]],"date-time":"2022-01-31T00:37:38Z","timestamp":1643589458000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":59,"title":["Challenges for Clinical Drug Development in Pulmonary Fibrosis"],"prefix":"10.3389","volume":"13","author":[{"given":"Eric S.","family":"White","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew","family":"Thomas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susanne","family":"Stowasser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kay","family":"Tetzlaff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,1,31]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"eaba1983","DOI":"10.1126\/sciadv.aba1983","article-title":"Single-Cell RNA-Seq Reveals Ectopic and Aberrant Lung-Resident Cell Populations in Idiopathic Pulmonary Fibrosis","volume":"6","author":"Adams","year":"2020","journal-title":"Sci. Adv."},{"key":"B2","doi-asserted-by":"publisher","first-page":"L1164","DOI":"10.1152\/ajplung.00220.2017","article-title":"IPF Lung Fibroblasts Have a Senescent Phenotype","volume":"313","author":"\u00c1lvarez","year":"2017","journal-title":"Am. J. Physiol.-Lung Cell Mol. Physiol."},{"key":"B3","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1038\/s41573-019-0034-3","article-title":"Adaptive Platform Trials: Definition, Design, Conduct and Reporting Considerations","volume":"18","author":"Angus","year":"2019","journal-title":"Nat. Rev. Drug Discov."},{"key":"B4","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1016\/s2213-2600(20)30554-3","article-title":"Pirfenidone in Patients with Progressive Fibrotic Interstitial Lung Diseases Other Than Idiopathic Pulmonary Fibrosis (RELIEF): A Double-Blind, Randomised, Placebo-Controlled, Phase 2b Trial","volume":"9","author":"Behr","year":"2021","journal-title":"Lancet Respir. Med."},{"key":"B5","doi-asserted-by":"publisher","first-page":"1902279","DOI":"10.1183\/13993003.02279-2019","article-title":"Survival and Course of Lung Function in the Presence or Absence of Antifibrotic Treatment in Patients with Idiopathic Pulmonary Fibrosis: Long-Term Results of the INSIGHTS-IPF Registry","volume":"56","author":"Behr","year":"2020","journal-title":"Eur. Respir. J."},{"key":"B6","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/j.rmed.2018.11.012","article-title":"Lung Function Outcomes in the INPULSIS\u00ae Trials of Nintedanib in Idiopathic Pulmonary Fibrosis","volume":"146","author":"Brown","year":"2019","journal-title":"Respir. Med."},{"key":"B7","doi-asserted-by":"publisher","first-page":"2000085","DOI":"10.1183\/13993003.00085-2020","article-title":"The Natural History of Progressive Fibrosing Interstitial Lung Diseases","volume":"55","author":"Brown","year":"2020","journal-title":"Eur. Respir. J."},{"key":"B8","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1016\/j.matbio.2018.03.015","article-title":"Endoplasmic Reticulum Stress in Pulmonary Fibrosis","author":"Burman","year":"2018","journal-title":"Matrix Biol."},{"key":"B9","doi-asserted-by":"publisher","first-page":"538","DOI":"10.1164\/rccm.200211-1311oc","article-title":"Changes in Clinical and Physiologic Variables Predict Survival in Idiopathic Pulmonary Fibrosis","volume":"168","author":"Collard","year":"2003","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"B78","doi-asserted-by":"publisher","first-page":"1059","DOI":"10.1002\/cpt.1804","article-title":"Current Statistical Considerations and Regulatory Perspectives on the Planning of Confirmatory Basket, Umbrella, and Platform Trials","volume":"107","author":"Collignon","year":"2020","journal-title":"Clin. Pharm. Therap."},{"key":"B10","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/j.ejps.2014.02.014","article-title":"Effect of Pirfenidone on Proliferation, TGF-\u03b2-Induced Myofibroblast Differentiation and Fibrogenic Activity of Primary Human Lung Fibroblasts","volume":"58","author":"Conte","year":"2014","journal-title":"Eur. J. Pharm. Sci."},{"key":"B11","doi-asserted-by":"publisher","first-page":"e143626","DOI":"10.1172\/jci.insight.143626","article-title":"Molecular Mapping of Interstitial Lung Disease Reveals a Phenotypically Distinct Senescent Basal Epithelial Cell Population","volume":"6","author":"DePianto","year":"2021","journal-title":"JCI Insight"},{"key":"B12","doi-asserted-by":"publisher","first-page":"1094","DOI":"10.1016\/j.chest.2020.08.2043","article-title":"Clinical Molecular Imaging of Pulmonary CXCR4 Expression to Predict Outcome of Pirfenidone Treatment in Idiopathic Pulmonary Fibrosis","volume":"159","author":"Derlin","year":"2021","journal-title":"Chest"},{"key":"B13","doi-asserted-by":"publisher","first-page":"100446","DOI":"10.1016\/j.conctc.2019.100446","article-title":"Minimizing Control Group Allocation in Randomized Trials Using Dynamic Borrowing of External Control Data - an Application to Second Line Therapy for Non-small Cell Lung Cancer","volume":"16","author":"Dron","year":"2019","journal-title":"Contemp. Clin. Trials Commun."},{"key":"B14","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1038\/ng.2609","article-title":"Genome-Wide Association Study Identifies Multiple Susceptibility Loci for Pulmonary Fibrosis","volume":"45","author":"Fingerlin","year":"2013","journal-title":"Nat. Genet."},{"key":"B15","doi-asserted-by":"publisher","first-page":"e000212","DOI":"10.1136\/bmjresp-2017-000212","article-title":"Design of the PF-ILD Trial: A Double-Blind, Randomised, Placebo-Controlled Phase III Trial of Nintedanib in Patients with Progressive Fibrosing Interstitial Lung Disease","volume":"4","author":"Flaherty","year":"2017","journal-title":"BMJ Open Respir. Res."},{"key":"B16","doi-asserted-by":"publisher","first-page":"1718","DOI":"10.1056\/nejmoa1908681","article-title":"Nintedanib in Progressive Fibrosing Interstitial Lung Diseases","volume":"381","author":"Flaherty","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"B17","doi-asserted-by":"publisher","first-page":"2445","DOI":"10.1016\/j.cmet.2021.10.015","article-title":"Efferocytosis Induces Macrophage Proliferation to Help Resolve Tissue Injury","volume":"33","author":"Gerlach","year":"2021","journal-title":"Cell Metab"},{"key":"B18","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1183\/09031936.02.00081102","article-title":"Serum Surfactant Proteins-A and -D as Biomarkers in Idiopathic Pulmonary Fibrosis","volume":"19","author":"Greene","year":"2002","journal-title":"Eur. Respir. J."},{"key":"B19","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1186\/s12931-018-0845-5","article-title":"The European IPF Registry (eurIPFreg): Baseline Characteristics and Survival of Patients with Idiopathic Pulmonary Fibrosis","volume":"19","author":"Guenther","year":"2018","journal-title":"Respir. Res."},{"key":"B20","doi-asserted-by":"publisher","first-page":"753806","DOI":"10.1101\/7538068","article-title":"Single-Cell RNA-Sequencing Reveals Profibrotic Roles of Distinct Epithelial and Mesenchymal Lineages in Pulmonary Fibrosis","volume":"6","author":"Habermann","year":"2019","journal-title":"Biorxiv"},{"key":"B21","doi-asserted-by":"publisher","first-page":"857","DOI":"10.1016\/s2213-2600(17)30349-1","article-title":"Validation of a 52-gene Risk Profile for Outcome Prediction in Patients with Idiopathic Pulmonary Fibrosis: an International, Multicentre, Cohort Study","volume":"5","author":"Herazo-Maya","year":"2017","journal-title":"Lancet Respir. Med."},{"key":"B22","doi-asserted-by":"publisher","first-page":"1941","DOI":"10.1136\/annrheumdis-2016-210823","article-title":"Nintedanib Inhibits Macrophage Activation and Ameliorates Vascular and Fibrotic Manifestations in the Fra2 Mouse Model of Systemic Sclerosis","volume":"76","author":"Huang","year":"2017","journal-title":"Ann. Rheum. Dis."},{"key":"B23","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.resinv.2012.02.001","article-title":"Utility of KL-6\/MUC1 in the Clinical Management of Interstitial Lung Diseases","volume":"50","author":"Ishikawa","year":"2012","journal-title":"Respir. Investig."},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1101\/2020.09.04.283408","article-title":"Airway Basal Cells Show a Dedifferentiated KRT17highPhenotype and Promote Fibrosis in Idiopathic Pulmonary Fibrosis","author":"Jaeger","year":"2020","journal-title":"bioRxiv"},{"key":"B25","doi-asserted-by":"publisher","first-page":"5187","DOI":"10.1183\/13993003.congress-2020.5187","article-title":"Effects of Nintedanib on Markers of Epithelial Damage in Subjects with IPF: Data from the INMARK Trial","author":"Jenkins","year":"2020","journal-title":"Eur. Respir. J."},{"key":"B26","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1186\/s12931-017-0556-3","article-title":"[18F]FDG PET\/CT Predicts Progression-free Survival in Patients with Idiopathic Pulmonary Fibrosis","volume":"18","author":"Justet","year":"2017","journal-title":"Respir. Res."},{"key":"B27","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1186\/s12931-021-01725-9","article-title":"Increased Monocyte Count and Red Cell Distribution Width as Prognostic Biomarkers in Patients with Idiopathic Pulmonary Fibrosis","volume":"22","author":"Karampitsakos","year":"2021","journal-title":"Respir. Res."},{"key":"B28","doi-asserted-by":"publisher","first-page":"1189","DOI":"10.1056\/nejmp1500526","article-title":"Forced Vital Capacity in Idiopathic Pulmonary Fibrosis--FDA Review of Pirfenidone and Nintedanib","volume":"372","author":"Karimi-Shah","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"B29","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1136\/thx.37.1.1","article-title":"Alveolitis: the Key to the Interstitial Lung Disorders","volume":"37","author":"Keogh","year":"1982","journal-title":"Thorax"},{"key":"B30","doi-asserted-by":"publisher","first-page":"2630","DOI":"10.1016\/s0140-6736(16)00232-4","article-title":"Safety and Efficacy of Subcutaneous Tocilizumab in Adults with Systemic Sclerosis (faSScinate): A Phase 2, Randomised, Controlled Trial","volume":"387","author":"Khanna","year":"2016","journal-title":"Lancet"},{"key":"B31","doi-asserted-by":"publisher","first-page":"963","DOI":"10.1016\/s2213-2600(20)30318-0","article-title":"Tocilizumab in Systemic Sclerosis: A Randomised, Double-Blind, Placebo-Controlled, Phase 3 Trial","volume":"8","author":"Khanna","year":"2020","journal-title":"Lancet Respir. Med."},{"key":"B32","doi-asserted-by":"publisher","first-page":"2083","DOI":"10.1056\/nejmoa1402582","article-title":"A Phase 3 Trial of Pirfenidone in Patients with Idiopathic Pulmonary Fibrosis","volume":"370","author":"King","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"B33","doi-asserted-by":"publisher","first-page":"1949","DOI":"10.1016\/s0140-6736(11)60052-4","article-title":"Idiopathic Pulmonary Fibrosis","volume":"378","author":"King","year":"2011","journal-title":"Lancet"},{"key":"B34","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1164\/rccm.200210-1245oc","article-title":"Fibrotic Idiopathic Interstitial Pneumonia: the Prognostic Value of Longitudinal Functional Trends","volume":"168","author":"Latsi","year":"2003","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"B35","doi-asserted-by":"publisher","first-page":"e52785","DOI":"10.15252\/embr.202152785","article-title":"An EZH2-Dependent Transcriptional Complex Promotes Aberrant Epithelial Remodelling after Injury","volume":"22","author":"Le","year":"2021","journal-title":"Embo Rep."},{"key":"B36","doi-asserted-by":"publisher","first-page":"225300","DOI":"10.1101\/2020.07.29.225300","article-title":"A Polycomb-Independent Role of EZH2 in TGF\u03b21-Damaged Epithelium Triggers a Fibrotic cascade with Mesenchymal Cells","volume":"729","author":"Le","year":"20202020","journal-title":"Biorxiv"},{"key":"B37","doi-asserted-by":"publisher","first-page":"684","DOI":"10.7326\/0003-4819-156-10-201205150-00004","article-title":"A Multidimensional Index and Staging System for Idiopathic Pulmonary Fibrosis","volume":"156","author":"Ley","year":"2012","journal-title":"Ann. Intern. Med."},{"key":"B38","doi-asserted-by":"publisher","first-page":"A2751","DOI":"10.1164\/ajrccm-conference.2020.201.1_meetingabstracts.a2751","article-title":"Evaluation of Collagen Neoepitope Biomarkers in a Phase 2 Trial of BMS-986020, a Lysophosphatidic Acid Receptor Antagonist, for the Treatment of Idiopathic Pulmonary Fibrosis","volume":"201","author":"Luo","year":"2020","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"B39","doi-asserted-by":"publisher","first-page":"946","DOI":"10.1016\/s2213-2600(17)30430-7","article-title":"An Epithelial Biomarker Signature for Idiopathic Pulmonary Fibrosis: An Analysis from the Multicentre PROFILE Cohort Study","volume":"5","author":"Maher","year":"2017","journal-title":"Lancet Respir. Med."},{"key":"B40","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1016\/s2213-2600(18)30181-4","article-title":"Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of GLPG1690, a Novel Autotaxin Inhibitor, to Treat Idiopathic Pulmonary Fibrosis (FLORA): A Phase 2a Randomised Placebo-Controlled Trial","volume":"6","author":"Maher","year":"2018","journal-title":"Lancet Respir. Med."},{"key":"B41","unstructured":"Effect of Nintedanib on Categorical Changes in Fvc in Patients with Progressive Fibrosing Ilds: Further Analyses of the INBUILD Trial\n            MaherT. M.\n            CerriS.\n            HallowellR. W.\n            KoschelD.\n            PopeJ.\n            TolleL.\n          2021"},{"key":"B42","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1186\/s12931-016-0427-3","article-title":"Serum Extracellular Vesicular miR-21-5p is a Predictor of the Prognosis in Idiopathic Pulmonary Fibrosis","volume":"17","author":"Makiguchi","year":"2016","journal-title":"Respir. Res."},{"key":"B43","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1016\/j.biocel.2007.08.011","article-title":"The Bleomycin Animal Model: A Useful Tool to Investigate Treatment Options for Idiopathic Pulmonary Fibrosis","volume":"40","author":"Moeller","year":"2008","journal-title":"Int. J. Biochem. Cell Biol."},{"key":"B44","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/j.rmed.2017.04.012","article-title":"The Performance of the GAP Model in Patients with Rheumatoid Arthritis Associated Interstitial Lung Disease","volume":"127","author":"Morisset","year":"2017","journal-title":"Respir. Med."},{"key":"B45","doi-asserted-by":"publisher","first-page":"1802441","DOI":"10.1183\/13993003.02441-2018","article-title":"Proliferating SPP1\/MERTK-Expressing Macrophages in Idiopathic Pulmonary Fibrosis","volume":"54","author":"Morse","year":"2019","journal-title":"Eur. Respir. J."},{"key":"B46","doi-asserted-by":"publisher","first-page":"2000039","DOI":"10.1002\/prca.202000039","article-title":"Untargeted Metabolomics of Human Plasma Reveal Lipid Markers Unique to Chronic Obstructive Pulmonary Disease and Idiopathic Pulmonary Fibrosis","volume":"15","author":"Nambiar","year":"2021","journal-title":"Prot. Clin. Appl."},{"key":"B47","doi-asserted-by":"publisher","first-page":"A7301","DOI":"10.1164\/ajrccm-conference.2019.199.1_meetingabstracts.a7301","article-title":"Omipalasib Modulates Extracellular Matrix Turnover in IPF Patients: Exploratory Biomarker Analysis from a Phase I Proof of Mechanism Study","volume":"199","author":"Nanthakumar","year":"2019","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"B48","doi-asserted-by":"publisher","first-page":"4008","DOI":"10.1172\/jci99287","article-title":"Expression of Mutant Sftpc in Murine Alveolar Epithelia Drives Spontaneous Lung Fibrosis","volume":"128","author":"Nureki","year":"2018","journal-title":"J. Clin. Invest."},{"key":"B49","doi-asserted-by":"publisher","first-page":"1475","DOI":"10.1164\/rccm.201505-1010oc","article-title":"TOLLIP, MUC5B, and the Response to N-Acetylcysteine Among Individuals with Idiopathic Pulmonary Fibrosis","volume":"192","author":"Oldham","year":"2015","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"B50","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1186\/s12931-019-1118-7","article-title":"Biomarkers of Collagen Synthesis Predict Progression in the PROFILE Idiopathic Pulmonary Fibrosis Cohort","volume":"20","author":"Organ","year":"2019","journal-title":"Respir. Res."},{"key":"B51","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1002\/cphy.c190017","article-title":"Oxidative Stress in Pulmonary Fibrosis","volume":"10","author":"Otoupalova","year":"2020","journal-title":"Compr. Physiol."},{"key":"B52","doi-asserted-by":"publisher","first-page":"1061","DOI":"10.1016\/j.chest.2018.08.1058","article-title":"Randomized, Double-Blind, Placebo-Controlled, Phase 2 Trial of BMS-986020, a Lysophosphatidic Acid Receptor Antagonist for the Treatment of Idiopathic Pulmonary Fibrosis","volume":"154","author":"Palmer","year":"2018","journal-title":"Chest"},{"key":"B53","doi-asserted-by":"publisher","first-page":"788","DOI":"10.1164\/rccm.2009-040gl","article-title":"An Official ATS\/ERS\/JRS\/ALAT Statement: Idiopathic Pulmonary Fibrosis: Evidence-Based Guidelines for Diagnosis and Management","volume":"183","author":"Raghu","year":"2012","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"B54","doi-asserted-by":"publisher","first-page":"1740","DOI":"10.1183\/13993003.01558-2014","article-title":"CC-chemokine Ligand 2 Inhibition in Idiopathic Pulmonary Fibrosis: a Phase 2 Trial of Carlumab","volume":"46","author":"Raghu","year":"2015","journal-title":"Eur. Respir. J."},{"key":"B55","doi-asserted-by":"publisher","first-page":"e44","DOI":"10.1164\/rccm.201807-1255st","article-title":"Diagnosis of Idiopathic Pulmonary Fibrosis. An Official ATS\/ERS\/JRS\/ALAT Clinical Practice Guideline","volume":"198","author":"Raghu","year":"2018","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"B56","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1165\/rcmb.2020-0542ma","article-title":"Persistent, Progressive Pulmonary Fibrosis and Epithelial Remodeling in Mice","volume":"64","author":"Redente","year":"2021","journal-title":"Am. J. Respir. Cell Mol. Biol."},{"key":"B57","doi-asserted-by":"publisher","first-page":"1517","DOI":"10.1164\/rccm.201712-2410oc","article-title":"Single-cell Transcriptomic Analysis of Human Lung Provides Insights into the Pathobiology of Pulmonary Fibrosis","volume":"199","author":"Reyfman","year":"2019","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"B58","doi-asserted-by":"publisher","first-page":"1079","DOI":"10.1056\/nejmoa1103690","article-title":"Efficacy of a Tyrosine Kinase Inhibitor in Idiopathic Pulmonary Fibrosis","volume":"365","author":"Richeldi","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"B59","doi-asserted-by":"publisher","first-page":"2071","DOI":"10.1056\/nejmoa1402584","article-title":"Efficacy and Safety of Nintedanib in Idiopathic Pulmonary Fibrosis","volume":"370","author":"Richeldi","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"B60","doi-asserted-by":"publisher","first-page":"e93","DOI":"10.1371\/journal.pmed.0050093","article-title":"MMP1 and MMP7 as Potential Peripheral Blood Biomarkers in Idiopathic Pulmonary Fibrosis","volume":"5","author":"Rosas","year":"2008","journal-title":"PLoS Med."},{"key":"B61","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1186\/s40248-017-0089-0","article-title":"Longitudinal Assessment of Bleomycin-Induced Lung Fibrosis by Micro-CT Correlates with Histological Evaluation in Mice","volume":"12","author":"Ruscitti","year":"2017","journal-title":"Multidiscip Respir. Med."},{"key":"B62","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1378\/chest.13-1474","article-title":"Predicting Survival across Chronic Interstitial Lung Disease: the ILD-GAP Model","volume":"145","author":"Ryerson","year":"2014","journal-title":"Chest"},{"key":"B63","doi-asserted-by":"publisher","first-page":"1571","DOI":"10.1164\/rccm.201612-2480oc","article-title":"Extracellular Mitochondrial DNA is Generated by Fibroblasts and Predicts Death in Idiopathic Pulmonary Fibrosis","volume":"196","author":"Ryu","year":"2017","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"B64","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1016\/j.rmed.2017.08.025","article-title":"Possible UIP Pattern on High-Resolution Computed Tomography is Associated with Better Survival Than Definite UIP in IPF Patients","volume":"131","author":"Salisbury","year":"2017","journal-title":"Respir. Med."},{"key":"B65","doi-asserted-by":"publisher","first-page":"136","DOI":"10.7326\/0003-4819-134-2-200101160-00015","article-title":"American Thoracic Society, European Respiratory Society, American College of Chest PhysiciansIdiopathic Pulmonary Fibrosis: Prevailing and Evolving Hypotheses about its Pathogenesis and Implications for Therapy","volume":"134","author":"Selman","year":"2001","journal-title":"Ann. Intern. Med."},{"key":"B66","doi-asserted-by":"publisher","first-page":"107798","DOI":"10.1016\/j.pharmthera.2020.107798","article-title":"Idiopathic Pulmonary Fibrosis: Disease Mechanisms and Drug Development","volume":"222","author":"Spagnolo","year":"2021","journal-title":"Pharmacol. Ther."},{"key":"B67","doi-asserted-by":"publisher","first-page":"3559","DOI":"10.1038\/s41467-020-17358-3","article-title":"Alveolar Regeneration through a Krt8+ Transitional Stem Cell State that Persists in Human Lung Fibrosis","volume":"11","author":"Strunz","year":"2020","journal-title":"Nat. Commun."},{"key":"B68","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1038\/ng.3278","article-title":"Exome Sequencing Links Mutations in PARN and RTEL1 with Familial Pulmonary Fibrosis and Telomere Shortening","volume":"47","author":"Stuart","year":"2015","journal-title":"Nat. Genet."},{"key":"B69","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1164\/rccm.201308-1483st","article-title":"An Official American Thoracic Society\/European Respiratory Society Statement: Update of the International Multidisciplinary Classification of the Idiopathic Interstitial Pneumonias","volume":"188","author":"Travis","year":"2013","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"B70","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.1002\/sctm.20-0526","article-title":"Resident Interstitial Lung Fibroblasts and Their Role in Alveolar Stem Cell Niche Development, Homeostasis, Injury, and Regeneration","volume":"10","author":"Ushakumary","year":"2021","journal-title":"Stem Cells Transl. Med."},{"key":"B71","doi-asserted-by":"publisher","first-page":"1800692","DOI":"10.1183\/13993003.00692-2018","article-title":"What\u2019s in a Name? That Which we Call IPF, by Any Other Name Would Act the same","volume":"51","author":"Wells","year":"2018","journal-title":"Eur. Respir. J."},{"key":"B72","doi-asserted-by":"publisher","first-page":"806","DOI":"10.1007\/s00259-017-3917-8","article-title":"Pulmonary 18F-FDG Uptake Helps Refine Current Risk Stratification in Idiopathic Pulmonary Fibrosis (IPF)","volume":"45","author":"Win","year":"2018","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"B73","doi-asserted-by":"publisher","first-page":"1900161","DOI":"10.1183\/13993003.00161-2019","article-title":"Potential of Nintedanib in Treatment of Progressive Fibrosing Interstitial Lung Diseases","volume":"54","author":"Wollin","year":"2019","journal-title":"Eur. Respir. J."},{"key":"B74","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1124\/jpet.113.208223","article-title":"Antifibrotic and Anti-Inflammatory Activity of the Tyrosine Kinase Inhibitor Nintedanib in Experimental Models of Lung Fibrosis","volume":"349","author":"Wollin","year":"2014","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"B75","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1016\/s2213-2600(18)30007-9","article-title":"Time for a Change: Is Idiopathic Pulmonary Fibrosis Still Idiopathic and Only Fibrotic","volume":"6","author":"Wolters","year":"2018","journal-title":"Lancet Respir. Med."},{"key":"B76","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1056\/nejmra1510062","article-title":"Master Protocols to Study Multiple Therapies, Multiple Diseases, or Both","volume":"377","author":"Woodcock","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"B77","doi-asserted-by":"publisher","first-page":"e000183","DOI":"10.1136\/bmjresp-2017-000183","article-title":"Metabolic Heterogeneity of Idiopathic Pulmonary Fibrosis: a Metabolomic Study","volume":"4","author":"Zhao","year":"2017","journal-title":"BMJ Open Respir. Res."}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2022.823085\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,1,31]],"date-time":"2022-01-31T00:37:41Z","timestamp":1643589461000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2022.823085\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1,31]]},"references-count":78,"alternative-id":["10.3389\/fphar.2022.823085"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2022.823085","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,1,31]]},"article-number":"823085"}}